The Brastianos laboratory studies genomic drivers of human brain tumors. Our overarching objective is to characterize molecular drivers of both progression in primary brain tumors and brain metastases, and accelerate the development of novel therapeutic approaches for these diseases. We recently discovered clinically significant genetic drivers in meningiomas, craniopharyngiomas, hemangioblastomas, glioneuronal tumors and brain metastases. We are currently investigating the role of these genomic drivers as potential therapeutic targets in a number of trials including several national NCI-sponsored multi-center clinical trials. Additionally, we are expanding our in vitro and in vivo investigations to further elucidate the molecular evolution of the metastatic process to the central nervous system.